Bartells Drugs, a subsidiary of Rite Aid, is currently under investigation by the Federal Trade Commission (FTC) for allegedly deceptive marketing practices. The FTC has accused Bartells of using deceptive tactics to market its products to consumers, including making false claims about the drug’s efficacy and safety.
Rite Aid has denied any wrongdoing and has said that it is fully cooperating with the FTC’s investigation.
If Bartells is found to have engaged in deceptive marketing practices, this could potentially lead to the company being fined by the FTC. It is unclear whether or not Rite Aid is responsible for any of Bartells’ alleged deceptive marketing practices, but the company’s cooperation with the FTC’s investigation is a positive sign.
Based on the FTC’s allegations, it appears that Bartells may have been using deceptive marketing practices for some time, and it will be interesting to see how the FTC’s investigation unfolds.
While it is still unclear what – if any – consequences Bartells may face, the company’s alleged deceptive marketing practices are troubling. If the FTC finds that Bartells has engaged in deceptive marketing practices, this could lead to negative consequences for the company, such as lost customers and decreased profits.
